XML 59 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment and Geographic Information (Tables)
12 Months Ended
Dec. 28, 2018
Segment Reporting [Abstract]  
Schedule of segment sales by product line
The following table presents sales by product line for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment sales by product line:
 
 
 
 
 
Medical
 
 
 
 
 
Cardio & Vascular
$
585,464

 
$
530,831

 
$
484,891

Cardiac & Neuromodulation
443,347

 
428,275

 
439,375

Advanced Surgical, Orthopedics & Portable Medical
133,225

 
120,006

 
109,557

Total Medical
1,162,036

 
1,079,112

 
1,033,823

Non-Medical
52,976

 
56,968

 
41,679

Total sales
$
1,215,012

 
$
1,136,080

 
$
1,075,502

Schedule of Revenue by Major Customers by Reporting Segments
A significant portion of the Company’s sales for fiscal years 2018, 2017 and 2016 and accounts receivable at December 28, 2018 and December 29, 2017 were to three customers as follows:
 
Sales
 
Accounts Receivable
 
2018
 
2017
 
2016
 
December 28,
2018
 
December 29,
2017
Customer A
21%
 
22%
 
24%
 
11%
 
11%
Customer B
19%
 
20%
 
21%
 
18%
 
21%
Customer C
12%
 
11%
 
12%
 
20%
 
20%
 
52%
 
53%
 
57%
 
49%
 
52%
Schedule of segment depreciation and amortization
The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment depreciation and amortization:
 
 
 
 
 
Medical
$
71,922

 
$
72,314

 
$
65,528

Non-Medical
1,364

 
2,675

 
2,346

Total depreciation and amortization included in segment
   income from operations
73,286

 
74,989

 
67,874

Unallocated depreciation and amortization
8,252

 
6,194

 
4,994

Total depreciation and amortization
$
81,538

 
$
81,183

 
$
72,868

Schedule of segment income (loss) from operations
The following table presents income from operations for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment income from operations:
 
 
 
 
 
Medical
$
224,893

 
$
197,212

 
$
170,101

Non-Medical
14,697

 
11,335

 
1,513

Total segment income from operations
239,590

 
208,547

 
171,614

Unallocated operating expenses
(84,035
)
 
(82,898
)
 
(78,691
)
Operating income
155,555

 
125,649

 
92,923

Unallocated expenses, net
(94,439
)
 
(76,390
)
 
(64,758
)
Income before benefit for income taxes
$
61,116

 
$
49,259

 
$
28,165

Schedule of long-lived tangible assets and identifable assets by geographic area
The following table presents PP&E by geographic area as of December 28, 2018 and December 29, 2017. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands).
 
December 28,
2018
 
December 29,
2017
Long-lived tangible assets by geographic area:
 
 
 
United States
$
151,851

 
$
157,808

Mexico
34,606

 
28,985

Ireland
32,190

 
33,992

Rest of world
12,622

 
14,395

Total
$
231,269

 
$
235,180

The following table presents total assets for the Company’s reportable segments as of December 28, 2018 and December 29, 2017 (in thousands).
 
December 28,
2018
 
December 29,
2017
Identifiable assets:
 
 
 
Medical(1)
$
2,186,565

 
$
2,687,227

Non-Medical
53,812

 
54,071

Total reportable segments
2,240,377

 
2,741,298

Unallocated assets
86,304

 
107,047

Total assets
$
2,326,681

 
$
2,848,345

Schedule of expenditures for tangible long-lived assets, excluding acquisitions
The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Expenditures for tangible long-lived assets:
 
 
 
 
 
Medical
$
34,615

 
$
20,896

 
$
27,014

Non-Medical
573

 
661

 
1,451

Total reportable segments
35,188

 
21,557

 
28,465

Unallocated long-lived tangible assets
6,110

 
8,783

 
8,251

Total expenditures
$
41,298

 
$
30,340

 
$
36,716

Schedule of sales by geographic area
The following table presents sales by significant country for fiscal years 2018, 2017 and 2016. In these tables, sales are allocated based on where the products are shipped (in thousands).
 
2018
 
2017
 
2016
Sales by geographic area:
 
 
 
 
 
United States
$
687,259

 
$
662,133

 
$
625,670

Non-Domestic locations:
 
 
 
 
 
Puerto Rico
146,500

 
140,184

 
162,343

Costa Rica
62,044

 
55,364

 
53,501

Rest of world
319,209

 
278,399

 
233,988

Total sales
$
1,215,012

 
$
1,136,080

 
$
1,075,502

Segment Reporting Disclosure [Text Block]
The following table presents sales by customer for fiscal year 2018.
Customer
 
Medical
 
Non-Medical
Customer A
 
22
%
 
%
Customer B
 
19
%
 
%
Customer C
 
12
%
 
%
Customer D
 
%
 
28
%
All other customers
 
47
%
 
72
%
(17.)     SEGMENT AND GEOGRAPHIC INFORMATION
The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting.
The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant.
(17.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
The following table presents sales by product line for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment sales by product line:
 
 
 
 
 
Medical
 
 
 
 
 
Cardio & Vascular
$
585,464

 
$
530,831

 
$
484,891

Cardiac & Neuromodulation
443,347

 
428,275

 
439,375

Advanced Surgical, Orthopedics & Portable Medical
133,225

 
120,006

 
109,557

Total Medical
1,162,036

 
1,079,112

 
1,033,823

Non-Medical
52,976

 
56,968

 
41,679

Total sales
$
1,215,012

 
$
1,136,080

 
$
1,075,502


A significant portion of the Company’s sales for fiscal years 2018, 2017 and 2016 and accounts receivable at December 28, 2018 and December 29, 2017 were to three customers as follows:
 
Sales
 
Accounts Receivable
 
2018
 
2017
 
2016
 
December 28,
2018
 
December 29,
2017
Customer A
21%
 
22%
 
24%
 
11%
 
11%
Customer B
19%
 
20%
 
21%
 
18%
 
21%
Customer C
12%
 
11%
 
12%
 
20%
 
20%
 
52%
 
53%
 
57%
 
49%
 
52%

The following table presents income from operations for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment income from operations:
 
 
 
 
 
Medical
$
224,893

 
$
197,212

 
$
170,101

Non-Medical
14,697

 
11,335

 
1,513

Total segment income from operations
239,590

 
208,547

 
171,614

Unallocated operating expenses
(84,035
)
 
(82,898
)
 
(78,691
)
Operating income
155,555

 
125,649

 
92,923

Unallocated expenses, net
(94,439
)
 
(76,390
)
 
(64,758
)
Income before benefit for income taxes
$
61,116

 
$
49,259

 
$
28,165


The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Segment depreciation and amortization:
 
 
 
 
 
Medical
$
71,922

 
$
72,314

 
$
65,528

Non-Medical
1,364

 
2,675

 
2,346

Total depreciation and amortization included in segment
   income from operations
73,286

 
74,989

 
67,874

Unallocated depreciation and amortization
8,252

 
6,194

 
4,994

Total depreciation and amortization
$
81,538

 
$
81,183

 
$
72,868


(17.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
The following table presents total assets for the Company’s reportable segments as of December 28, 2018 and December 29, 2017 (in thousands).
 
December 28,
2018
 
December 29,
2017
Identifiable assets:
 
 
 
Medical(1)
$
2,186,565

 
$
2,687,227

Non-Medical
53,812

 
54,071

Total reportable segments
2,240,377

 
2,741,298

Unallocated assets
86,304

 
107,047

Total assets
$
2,326,681

 
$
2,848,345


__________ 
(1) 
Medical segment identifiable assets at December 29, 2017 includes $451.4 million of assets held sale.
The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2018, 2017 and 2016 (in thousands).
 
2018
 
2017
 
2016
Expenditures for tangible long-lived assets:
 
 
 
 
 
Medical
$
34,615

 
$
20,896

 
$
27,014

Non-Medical
573

 
661

 
1,451

Total reportable segments
35,188

 
21,557

 
28,465

Unallocated long-lived tangible assets
6,110

 
8,783

 
8,251

Total expenditures
$
41,298

 
$
30,340

 
$
36,716


Geographic Area Information
The following table presents sales by significant country for fiscal years 2018, 2017 and 2016. In these tables, sales are allocated based on where the products are shipped (in thousands).
 
2018
 
2017
 
2016
Sales by geographic area:
 
 
 
 
 
United States
$
687,259

 
$
662,133

 
$
625,670

Non-Domestic locations:
 
 
 
 
 
Puerto Rico
146,500

 
140,184

 
162,343

Costa Rica
62,044

 
55,364

 
53,501

Rest of world
319,209

 
278,399

 
233,988

Total sales
$
1,215,012

 
$
1,136,080

 
$
1,075,502


The following table presents PP&E by geographic area as of December 28, 2018 and December 29, 2017. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands).
 
December 28,
2018
 
December 29,
2017
Long-lived tangible assets by geographic area:
 
 
 
United States
$
151,851

 
$
157,808

Mexico
34,606

 
28,985

Ireland
32,190

 
33,992

Rest of world
12,622

 
14,395

Total
$
231,269

 
$
235,180


(17.)     SEGMENT AND GEOGRAPHIC INFORMATION (Continued)
Disaggregation of Revenue by Segment
In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors.
The following table presents sales by customer for fiscal year 2018.
Customer
 
Medical
 
Non-Medical
Customer A
 
22
%
 
%
Customer B
 
19
%
 
%
Customer C
 
12
%
 
%
Customer D
 
%
 
28
%
All other customers
 
47
%
 
72
%

The following table presents revenues by ship to country for fiscal year 2018.
Ship to Location
 
Medical
 
Non-Medical
United States
 
56%
 
66%
Puerto Rico
 
13%
 
—%
Canada
 
—%
 
11%
All other Countries
 
31%
 
23%